SG11201811804QA - Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors - Google Patents

Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors

Info

Publication number
SG11201811804QA
SG11201811804QA SG11201811804QA SG11201811804QA SG11201811804QA SG 11201811804Q A SG11201811804Q A SG 11201811804QA SG 11201811804Q A SG11201811804Q A SG 11201811804QA SG 11201811804Q A SG11201811804Q A SG 11201811804QA SG 11201811804Q A SG11201811804Q A SG 11201811804QA
Authority
SG
Singapore
Prior art keywords
ingelheim
international
rhein
gmbh
ghrelin
Prior art date
Application number
SG11201811804QA
Other languages
English (en)
Inventor
Cédrickx Godbout
Thomas Trieselmann
Viktor Vintonyak
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of SG11201811804QA publication Critical patent/SG11201811804QA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11201811804QA 2016-08-05 2017-07-31 Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors SG11201811804QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16183047 2016-08-05
PCT/EP2017/069274 WO2018024653A1 (en) 2016-08-05 2017-07-31 Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors

Publications (1)

Publication Number Publication Date
SG11201811804QA true SG11201811804QA (en) 2019-01-30

Family

ID=56609762

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201811804QA SG11201811804QA (en) 2016-08-05 2017-07-31 Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors

Country Status (32)

Country Link
US (3) US9994591B2 (ru)
EP (1) EP3494120B1 (ru)
JP (1) JP6651054B2 (ru)
KR (1) KR102496075B1 (ru)
CN (1) CN109843891B (ru)
AR (1) AR109296A1 (ru)
AU (1) AU2017307033B2 (ru)
CA (1) CA3033058A1 (ru)
CL (1) CL2019000274A1 (ru)
CO (1) CO2019000601A2 (ru)
CY (1) CY1124381T1 (ru)
DK (1) DK3494120T3 (ru)
EA (1) EA037277B1 (ru)
ES (1) ES2874587T3 (ru)
HR (1) HRP20210908T1 (ru)
HU (1) HUE054928T2 (ru)
IL (1) IL264506B (ru)
LT (1) LT3494120T (ru)
MA (1) MA45843B1 (ru)
MX (1) MX2019001427A (ru)
MY (1) MY197064A (ru)
PE (1) PE20190414A1 (ru)
PH (1) PH12019500254A1 (ru)
PL (1) PL3494120T3 (ru)
PT (1) PT3494120T (ru)
RS (1) RS61937B1 (ru)
SA (1) SA519401039B1 (ru)
SG (1) SG11201811804QA (ru)
SI (1) SI3494120T1 (ru)
TW (1) TWI749042B (ru)
UA (1) UA124267C2 (ru)
WO (1) WO2018024653A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019149658A1 (en) * 2018-02-02 2019-08-08 Boehringer Ingelheim International Gmbh Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
MX2020007994A (es) 2018-02-02 2020-09-09 Boehringer Ingelheim Int Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat).
EP3746450B1 (en) * 2018-02-02 2022-03-16 Boehringer Ingelheim International GmbH Heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
CR20200332A (es) * 2018-02-02 2020-09-03 Boehringer Ingelheim Int Derivados de oxadiazolopiridina sustitidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat)
JP2023526351A (ja) 2020-05-22 2023-06-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルキル7-アミノ-5-メチル-[1,2,5]オキサジアゾロ[3,4-b]ピリジンカルボキシレートの製造方法
EP4153600A1 (en) 2020-05-22 2023-03-29 Boehringer Ingelheim International GmbH Continuous process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate
CN112014340A (zh) * 2020-09-01 2020-12-01 广西玮美生物科技有限公司 非人灵长类动物胃饥饿素的检测方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2241496B1 (es) 2004-04-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridina.
JP2010512366A (ja) 2006-12-11 2010-04-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Mch拮抗活性を有する新規ピリダジン誘導体及びこれらの化合物を含む薬物
EP2111414B1 (en) 2007-02-15 2014-07-02 Indiana University Research and Technology Corporation Glucagon/glp-1 receptor co-agonists
DK2158214T3 (da) 2007-06-15 2011-12-05 Zealand Pharma As Glukagonanaloger
BRPI0823379A2 (pt) 2008-12-15 2015-07-14 Zealand Pharma As Análogos de glucagon
MX2011006314A (es) 2008-12-15 2011-09-22 Zealand Pharma As Analogos de glucagon.
AU2008365555B2 (en) 2008-12-15 2016-01-14 Zealand Pharma A/S Glucagon analogues
EA020596B1 (ru) 2008-12-15 2014-12-30 Зилэнд Фарма А/С Аналоги глюкагона
JP6054742B2 (ja) 2009-07-13 2016-12-27 ジーランド ファーマ アクティーゼルスカブ アシル化グルカゴン類似体
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
AU2011269430A1 (en) 2010-06-24 2013-01-10 Zealand Pharma A/S Glucagon analogues
CN104144696A (zh) 2011-12-23 2014-11-12 西兰制药公司 胰高血糖素类似物
WO2013125732A1 (en) * 2012-02-24 2013-08-29 Takeda Pharmaceutical Company Limited Aromatic ring compound
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
UA118034C2 (uk) 2013-11-14 2018-11-12 Елі Ліллі Енд Компані Заміщений піперидилетилпіримідин як інгібітор грелін-o-ацилтрансферази
US20170275249A1 (en) * 2014-09-17 2017-09-28 The Regents Of The University Of California Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase
AR104672A1 (es) 2015-04-15 2017-08-09 Lilly Co Eli Inhibidores de grelina o-aciltransferasa
AR104673A1 (es) 2015-04-15 2017-08-09 Lilly Co Eli Inhibidores de grelina o-aciltransferasa
MX2020007994A (es) 2018-02-02 2020-09-09 Boehringer Ingelheim Int Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat).
EP3746450B1 (en) 2018-02-02 2022-03-16 Boehringer Ingelheim International GmbH Heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
WO2019149658A1 (en) * 2018-02-02 2019-08-08 Boehringer Ingelheim International Gmbh Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
CR20200332A (es) 2018-02-02 2020-09-03 Boehringer Ingelheim Int Derivados de oxadiazolopiridina sustitidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat)

Also Published As

Publication number Publication date
TW201817735A (zh) 2018-05-16
CA3033058A1 (en) 2018-02-08
CO2019000601A2 (es) 2019-02-08
PT3494120T (pt) 2021-05-26
US20180251476A1 (en) 2018-09-06
WO2018024653A1 (en) 2018-02-08
RS61937B1 (sr) 2021-07-30
US9994591B2 (en) 2018-06-12
HUE054928T2 (hu) 2021-10-28
EP3494120A1 (en) 2019-06-12
JP6651054B2 (ja) 2020-02-19
US20180037594A1 (en) 2018-02-08
SA519401039B1 (ar) 2021-11-25
US10308667B2 (en) 2019-06-04
EP3494120B1 (en) 2021-03-17
EA201990418A1 (ru) 2019-08-30
CY1124381T1 (el) 2022-07-22
KR20190035859A (ko) 2019-04-03
IL264506A (en) 2019-02-28
UA124267C2 (uk) 2021-08-18
PH12019500254A1 (en) 2019-06-03
CN109843891B (zh) 2021-11-23
CN109843891A (zh) 2019-06-04
PL3494120T3 (pl) 2021-09-20
MA45843B1 (fr) 2021-06-30
EA037277B1 (ru) 2021-03-03
CL2019000274A1 (es) 2019-05-03
SI3494120T1 (sl) 2021-08-31
TWI749042B (zh) 2021-12-11
USRE49446E1 (en) 2023-03-07
ES2874587T3 (es) 2021-11-05
KR102496075B1 (ko) 2023-02-06
MX2019001427A (es) 2019-06-10
NZ749290A (en) 2021-08-27
PE20190414A1 (es) 2019-03-19
MA45843A (fr) 2019-06-12
AU2017307033A1 (en) 2019-01-17
MY197064A (en) 2023-05-24
DK3494120T3 (da) 2021-05-31
HRP20210908T1 (hr) 2021-09-03
IL264506B (en) 2021-03-25
AR109296A1 (es) 2018-11-14
JP2019524786A (ja) 2019-09-05
LT3494120T (lt) 2021-05-25
AU2017307033B2 (en) 2020-11-26

Similar Documents

Publication Publication Date Title
SG11201811804QA (en) Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors
SG11201809126RA (en) Aromatic sulfonamide derivatives
SG11201909960UA (en) Methods for improving memory and cognition and for treating memory and cognitive disorders
SG11201811470PA (en) Pyrazolopyrimidine derivatives as kinase inhibitor
SG11201808566WA (en) Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201408605UA (en) Methods for biodegradable derivatization of cellulosic surfaces
SG11201500005SA (en) Pyrimidine pyrazolyl derivatives
SG11201805368YA (en) Anthelmintic depsipeptide compounds
SG11201907804QA (en) Pharmaceutical composition comprising selexipag
SG11201810177VA (en) Pet-imaging immunomodulators
SG11201408750VA (en) NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS
SG11201901850XA (en) Dopamine-b-hydroxylase inhibitors
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201808686VA (en) Synthesis of indazoles
SG11201803692PA (en) Anti-5t4 antibodies and antibody-drug conjugates
SG11201900633XA (en) Piperidine cxcr7 receptor modulators
SG11201809531SA (en) BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF
SG11201809560QA (en) Enhancer of zeste homolog 2 inhibitors
SG11201909735YA (en) Therapeutic compounds and compositions, and methods of use thereof
SG11201900336YA (en) Radioligands for imaging the ido1 enzyme
SG11201407303SA (en) Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
SG11201901689YA (en) Compounds for treating diseases associated with a mitochondrial dysfonction
SG11201809687TA (en) Pyridinyl derivatives, pharmaceutical compositions and uses thereof as aoc3 inhibitors